Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Non Operating Income (2020 - 2025)

Historic Non Operating Income for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $395000.0.

  • Mirum Pharmaceuticals' Non Operating Income rose 13633.85% to $395000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 23564.21%. This contributed to the annual value of $1.2 million for FY2024, which is 14295.33% up from last year.
  • As of Q3 2025, Mirum Pharmaceuticals' Non Operating Income stood at $395000.0, which was up 13633.85% from $86000.0 recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Non Operating Income registered a high of $2.1 million during Q1 2025, and its lowest value of -$3.1 million during Q4 2023.
  • Its 5-year average for Non Operating Income is $40052.6, with a median of -$17000.0 in 2021.
  • In the last 5 years, Mirum Pharmaceuticals' Non Operating Income crashed by 335882.35% in 2022 and then soared by 78854.17% in 2023.
  • Mirum Pharmaceuticals' Non Operating Income (Quarter) stood at -$17000.0 in 2021, then crashed by 3358.82% to -$588000.0 in 2022, then tumbled by 420.58% to -$3.1 million in 2023, then surged by 107.55% to $231000.0 in 2024, then surged by 71.0% to $395000.0 in 2025.
  • Its last three reported values are $395000.0 in Q3 2025, $86000.0 for Q2 2025, and $2.1 million during Q1 2025.